Cabaletta Bio Inc Ordinary Shares CABA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CABA is a good fit for your portfolio.
News
-
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
-
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
-
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
-
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
-
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
-
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs
Trading Information
- Previous Close Price
- $12.95
- Day Range
- $11.70–12.46
- 52-Week Range
- $7.69–26.30
- Bid/Ask
- $12.29 / $12.31
- Market Cap
- $593.95 Mil
- Volume/Avg
- 937,024 / 980,775
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 103
- Website
- https://www.cabalettabio.com
Comparables
Valuation
|
Metric
|
CABA
|
CRBU
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.62 | 0.92 | 0.78 |
Price/Sales | — | 8.24 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CABA
|
CRBU
|
VOR
|
|---|---|---|---|
Quick Ratio | 15.08 | 11.75 | 8.81 |
Current Ratio | 15.29 | 11.97 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
CABA
CRBU
VOR
Profitability
|
Metric
|
CABA
|
CRBU
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −33.85% | −23.27% | −41.83% |
Return on Equity (Normalized) | −36.70% | −28.24% | −51.69% |
Return on Invested Capital (Normalized) | −40.04% | −26.03% | −47.03% |
Return on Assets
CABA
CRBU
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ntmkmdlw | Tzw | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xsqfnwq | Ksnxqs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mzldrxy | Ntgyhn | $99.5 Bil | |
MRNA
| Moderna Inc | Dyzdvnzfc | Pzg | $38.8 Bil | |
ARGX
| argenx SE ADR | Xzktckyb | Bdrd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qnhjzksv | Zsh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nlgydtns | Yxjcc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twphvwmd | Vkmgj | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mdjsyfqcc | Fnsqtgn | $12.5 Bil | |
INCY
| Incyte Corp | Qpgtdwy | Nhxftlk | $11.6 Bil |